Share Price and Basic Stock Data
Last Updated: September 3, 2024, 11:03 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ortin Laboratories Ltd operates in the pharmaceuticals sector, a field that has faced both challenges and opportunities in recent years. The company’s revenue trajectory has been quite tumultuous, especially when compared to its historical performance. Reported sales for the fiscal year ending March 2024 stood at ₹2.28 Cr, a stark decline from ₹6.00 Cr in the previous year and a significant drop from ₹8.23 Cr in FY 2022. The quarterly sales figures reflect this trend, with a particularly sharp fall in the latest quarters. For instance, sales dropped to just ₹0.14 Cr in December 2023, highlighting potential operational hurdles or market challenges that the company is grappling with. This decline raises questions about the company’s market positioning and ability to adapt to changing industry dynamics.
Profitability and Efficiency Metrics
Profitability metrics for Ortin Laboratories paint a concerning picture. The company’s net profit for the fiscal year 2024 was reported at a loss of ₹8.04 Cr, significantly worse than the previous year’s loss of ₹0.09 Cr. The operating profit margin (OPM) is particularly alarming, standing at a staggering -1,016.67% for the latest quarter, which indicates severe operational inefficiencies. The return on equity (ROE) at 118% appears strong superficially, but this is skewed by the negative net profit, leaving investors questioning its sustainability. Moreover, the interest coverage ratio (ICR) of 3.63x suggests that while the company can cover its interest obligations, the negative net profit raises red flags about its overall profitability. The downward trend in profit reflects not just operational challenges but potentially deeper issues within the company’s cost structure or market demand.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ortin Laboratories reveals a mixed picture of financial health. As of March 2024, the company reported total borrowings of ₹1.80 Cr, a decrease from previous years, which might suggest a strategy to reduce debt levels. However, the reserves have turned negative at -₹5.31 Cr, indicating that the company has not been able to retain earnings to bolster its financial foundation. The price-to-book value ratio stands at 1.97x, which may seem reasonable, yet the negative reserves and ongoing losses raise questions about the intrinsic value of the stock. The declining total assets from ₹21.20 Cr in FY 2023 to ₹6.59 Cr in FY 2024 further illustrate a worrying trend of asset depletion. This situation necessitates a closer look at the company’s ability to generate future cash flows and sustain operations without a robust reserve base.
Shareholding Pattern and Investor Confidence
Currently, Ortin Laboratories does not report any significant shareholding details, with no promoters or institutional investors listed, which can be a source of concern for retail investors. The absence of major stakeholders often translates to a lack of confidence in the company’s future, as institutional backing usually signals a level of trust in a company’s management and strategy. The lack of public information on shareholder sentiment adds to the uncertainty surrounding the stock. Retail investors may find it challenging to gauge market confidence in Ortin, especially given the recent trends of declining revenues and increasing losses. The absence of a diversified shareholder base could also mean that the stock is more susceptible to volatility, raising the stakes for potential investors.
Outlook, Risks, and Final Insight
Looking ahead, Ortin Laboratories faces a myriad of risks that could impact its operational viability. The drastic decline in sales and profitability suggests that the company needs urgent strategic realignment to navigate the competitive pharmaceutical landscape effectively. Potential investors should consider the operational inefficiencies highlighted by the negative OPM and net profits, which could hinder any recovery efforts. Additionally, the financial instability reflected in the negative reserves poses a significant risk to long-term sustainability. On the flip side, if the company can stabilize its operations and improve its market presence, there is potential for recovery. However, the road ahead seems fraught with challenges, and investors would do well to approach Ortin Laboratories with caution, weighing the risks against any signs of a turnaround in operational performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,163.06 Cr | 1,151.80 | 52.58 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.76 | 1.98 | 2.29 | 1.66 | 2.45 | 2.62 | 0.79 | 1.17 | 1.49 | 1.57 | 0.27 | 0.14 | 0.30 |
| Expenses | 1.55 | 1.61 | 2.00 | 1.65 | 2.59 | 2.41 | 1.01 | 0.55 | 1.52 | 1.39 | 1.17 | 2.74 | 3.35 |
| Operating Profit | 0.21 | 0.37 | 0.29 | 0.01 | -0.14 | 0.21 | -0.22 | 0.62 | -0.03 | 0.18 | -0.90 | -2.60 | -3.05 |
| OPM % | 11.93% | 18.69% | 12.66% | 0.60% | -5.71% | 8.02% | -27.85% | 52.99% | -2.01% | 11.46% | -333.33% | -1,857.14% | -1,016.67% |
| Other Income | 0.05 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.19 | 0.18 | 0.19 | 0.19 | 0.24 | 0.10 | 0.09 | 0.10 | 0.12 | 0.11 | 0.15 | 0.14 | 0.08 |
| Depreciation | 0.07 | 0.07 | 0.07 | -0.07 | 0.23 | 0.07 | 0.07 | 0.07 | 0.03 | 0.06 | 0.06 | 0.06 | 0.05 |
| Profit before tax | 0.00 | 0.12 | 0.07 | -0.11 | -0.61 | 0.04 | -0.38 | 0.45 | -0.21 | 0.01 | -1.11 | -2.80 | -3.18 |
| Tax % | 25.00% | 28.57% | -18.18% | -24.59% | 1,150.00% | -121.05% | 0.00% | -4.76% | 0.00% | 1.80% | -0.71% | 30.19% | |
| Net Profit | 0.80 | 0.09 | 0.05 | -0.09 | -0.45 | -0.43 | 0.08 | 0.46 | -0.20 | 0.02 | -1.12 | -2.79 | -4.14 |
| EPS in Rs | 0.98 | 0.11 | 0.06 | -0.11 | -0.55 | -0.53 | 0.10 | 0.57 | -0.25 | 0.02 | -1.38 | -3.43 | -5.09 |
Last Updated: Unknown
Below is a detailed analysis of the quarterly data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Sales, as of Mar 2024, the value is 0.30 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Dec 2023) to 0.30 Cr., marking an increase of 0.16 Cr..
- For Expenses, as of Mar 2024, the value is 3.35 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.74 Cr. (Dec 2023) to 3.35 Cr., marking an increase of 0.61 Cr..
- For Operating Profit, as of Mar 2024, the value is -3.05 Cr.. The value appears to be declining and may need further review. It has decreased from -2.60 Cr. (Dec 2023) to -3.05 Cr., marking a decrease of 0.45 Cr..
- For OPM %, as of Mar 2024, the value is -1,016.67%. The value appears strong and on an upward trend. It has increased from -1,857.14% (Dec 2023) to -1,016.67%, marking an increase of 840.47%.
- For Other Income, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded 0.00 Cr..
- For Interest, as of Mar 2024, the value is 0.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.14 Cr. (Dec 2023) to 0.08 Cr., marking a decrease of 0.06 Cr..
- For Depreciation, as of Mar 2024, the value is 0.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Dec 2023) to 0.05 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Mar 2024, the value is -3.18 Cr.. The value appears to be declining and may need further review. It has decreased from -2.80 Cr. (Dec 2023) to -3.18 Cr., marking a decrease of 0.38 Cr..
- For Tax %, as of Mar 2024, the value is 30.19%. The value appears to be increasing, which may not be favorable. It has increased from -0.71% (Dec 2023) to 30.19%, marking an increase of 30.90%.
- For Net Profit, as of Mar 2024, the value is -4.14 Cr.. The value appears to be declining and may need further review. It has decreased from -2.79 Cr. (Dec 2023) to -4.14 Cr., marking a decrease of 1.35 Cr..
- For EPS in Rs, as of Mar 2024, the value is -5.09. The value appears to be declining and may need further review. It has decreased from -3.43 (Dec 2023) to -5.09, marking a decrease of 1.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: Unknown
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.74 | 67.00 | 60.29 | 62.72 | 61.57 | 79.63 | 167.51 | 197.36 | 8.16 | 8.23 | 6.00 | 2.28 |
| Expenses | 68.17 | 60.90 | 53.80 | 56.83 | 56.12 | 74.22 | 160.83 | 191.66 | 6.92 | 7.85 | 5.47 | 8.65 |
| Operating Profit | 6.57 | 6.10 | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.70 | 1.24 | 0.38 | 0.53 | -6.37 |
| OPM % | 8.79% | 9.10% | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.20% | 4.62% | 8.83% | -279.39% |
| Other Income | 0.24 | 0.81 | 0.00 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | 0.00 |
| Interest | 3.55 | 3.72 | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.40 | 0.48 |
| Depreciation | 1.40 | 1.51 | 1.64 | 1.65 | 1.70 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 |
| Profit before tax | 1.86 | 1.68 | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | -0.53 | -0.11 | -7.08 |
| Tax % | 41.40% | 29.17% | 32.33% | 41.01% | 55.75% | 0.00% | 30.43% | 181.69% | -623.08% | -24.53% | -18.18% | 13.56% |
| Net Profit | 1.09 | 1.19 | 0.90 | 0.83 | 0.50 | 0.68 | 1.28 | -0.56 | 0.95 | -0.40 | -0.09 | -8.04 |
| EPS in Rs | 0.64 | 0.70 | 0.53 | 0.49 | 0.30 | 0.40 | 0.76 | -0.33 | 1.17 | -0.49 | -0.11 | -9.89 |
| Dividend Payout % | 38.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.17% | -24.37% | -7.78% | -39.76% | 36.00% | 88.24% | -143.75% | 269.64% | -142.11% | 77.50% | -8833.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -33.54% | 16.59% | -31.98% | 75.76% | 52.24% | -231.99% | 413.39% | -411.75% | 219.61% | -8910.83% |
Ortin Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: Unknown
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 |
| Reserves | 3.84 | 5.02 | 5.50 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | -5.31 |
| Borrowings | 17.92 | 18.68 | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.80 |
| Other Liabilities | 34.80 | 31.93 | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 1.97 |
| Total Liabilities | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
| Fixed Assets | 24.77 | 23.90 | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.40 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0.00 |
| Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 48.70 | 48.64 | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.58 |
| Total Assets | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
Below is a detailed analysis of the balance sheet data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2024, the value is 8.13 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 8.13 Cr..
- For Reserves, as of Mar 2024, the value is -5.31 Cr.. The value appears to be declining and may need further review. It has decreased from 2.73 Cr. (Mar 2023) to -5.31 Cr., marking a decrease of 8.04 Cr..
- For Borrowings, as of Mar 2024, the value is 1.80 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 6.45 Cr. (Mar 2023) to 1.80 Cr., marking a decrease of 4.65 Cr..
- For Other Liabilities, as of Mar 2024, the value is 1.97 Cr.. The value appears to be improving (decreasing). It has decreased from 3.89 Cr. (Mar 2023) to 1.97 Cr., marking a decrease of 1.92 Cr..
- For Total Liabilities, as of Mar 2024, the value is 6.59 Cr.. The value appears to be improving (decreasing). It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
- For Fixed Assets, as of Mar 2024, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 13.96 Cr. (Mar 2023) to 0.01 Cr., marking a decrease of 13.95 Cr..
- For CWIP, as of Mar 2024, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.43 Cr. (Mar 2023) to 0.00 Cr., marking a decrease of 0.43 Cr..
- For Investments, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2024, the value is 6.58 Cr.. The value appears to be declining and may need further review. It has decreased from 6.81 Cr. (Mar 2023) to 6.58 Cr., marking a decrease of 0.23 Cr..
- For Total Assets, as of Mar 2024, the value is 6.59 Cr.. The value appears to be declining and may need further review. It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
However, the Borrowings (1.80 Cr.) are higher than the Reserves (-5.31 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -11.35 | -12.58 | -14.47 | -14.96 | -11.89 | -11.93 | -12.79 | -13.87 | -5.70 | -5.76 | -5.92 | -8.17 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
No data available for the Shareholding
No data available for the Shareholding Pattern chart.
No data available for the No. of Shareholders chart.
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 12 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 2.73 |
| Diluted EPS (Rs.) | 2.73 |
| Cash EPS (Rs.) | 3.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.47 |
| Revenue From Operations / Share (Rs.) | 50.63 |
| PBDIT / Share (Rs.) | 6.99 |
| PBIT / Share (Rs.) | 6.13 |
| PBT / Share (Rs.) | 4.20 |
| Net Profit / Share (Rs.) | 2.73 |
| NP After MI And SOA / Share (Rs.) | 2.73 |
| PBDIT Margin (%) | 13.81 |
| PBIT Margin (%) | 12.10 |
| PBT Margin (%) | 8.30 |
| Net Profit Margin (%) | 5.38 |
| NP After MI And SOA Margin (%) | 5.38 |
| Return on Networth / Equity (%) | 18.85 |
| Return on Capital Employeed (%) | 34.77 |
| Return On Assets (%) | 5.67 |
| Long Term Debt / Equity (X) | 0.11 |
| Total Debt / Equity (X) | 0.58 |
| Current Ratio (X) | 1.11 |
| Quick Ratio (X) | 0.82 |
| Interest Coverage Ratio (X) | 3.63 |
| Interest Coverage Ratio (Post Tax) (X) | 2.42 |
| Enterprise Value (Cr.) | 62.39 |
| EV / Net Operating Revenue (X) | 0.72 |
| EV / EBITDA (X) | 5.27 |
| MarketCap / Net Operating Revenue (X) | 0.56 |
| Price / BV (X) | 1.97 |
| Price / Net Operating Revenue (X) | 0.56 |
| EarningsYield | 0.09 |
After reviewing the key financial ratios for Ortin Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 12, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 12, the value is 3.59. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 12, the value is 50.63. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 12, the value is 6.99. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 12, the value is 6.13. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 12, the value is 4.20. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 12, the value is 13.81. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 12, the value is 12.10. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 12, the value is 8.30. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 12, the value is 5.38. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 12, the value is 5.38. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 12, the value is 18.85. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 12, the value is 34.77. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 12, the value is 5.67. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 12, the value is 0.11. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 12, the value is 0.58. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 12, the value is 1.11. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 12, the value is 0.82. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 12, the value is 3.63. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 12, the value is 2.42. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 12, the value is 62.39. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 12, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 12, the value is 5.27. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 12, the value is 1.97. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 12, the value is 0.09. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ortin Laboratories Ltd:
- Net Profit Margin: 5.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 34.77% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.85% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.58)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.58
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | D. No. 1-8-B4, Ground Floor, F3 HIG, Block-4, Street No.3, Hyderabad Telangana 500044 | info@ortinlabsindia.com http://www.ortinlabsindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murali Krishna Rayaprolu | Chairman & Ind.Director |
| Mr. S Murali Krishna Murthy | Managing Director |
| Mr. S Srinivas Kumar | Whole Time Director |
| Mr. S Balaji Venkateswarlu | Non Executive Director |
| Mr. B Gopal Reddy | Independent Director |
| Ms. Pottur Sujatha | Independent Director |
Ortin Laboratories Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹18.00 |
| Previous Day | ₹18.48 |
FAQ
What is the intrinsic value of Ortin Laboratories Ltd?
Ortin Laboratories Ltd's intrinsic value (as of 04 December 2025) is 50.12 which is 149.35% higher the current market price of 20.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 16.4 Cr. market cap, FY2025-2026 high/low of 26.4/16.2, reserves of ₹-5.31 Cr, and liabilities of 6.59 Cr.
What is the Market Cap of Ortin Laboratories Ltd?
The Market Cap of Ortin Laboratories Ltd is 16.4 Cr..
What is the current Stock Price of Ortin Laboratories Ltd as on 04 December 2025?
The current stock price of Ortin Laboratories Ltd as on 04 December 2025 is 20.1.
What is the High / Low of Ortin Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ortin Laboratories Ltd stocks is 26.4/16.2.
What is the Stock P/E of Ortin Laboratories Ltd?
The Stock P/E of Ortin Laboratories Ltd is .
What is the Book Value of Ortin Laboratories Ltd?
The Book Value of Ortin Laboratories Ltd is 3.47.
What is the Dividend Yield of Ortin Laboratories Ltd?
The Dividend Yield of Ortin Laboratories Ltd is 0.00 %.
What is the ROCE of Ortin Laboratories Ltd?
The ROCE of Ortin Laboratories Ltd is 60.2 %.
What is the ROE of Ortin Laboratories Ltd?
The ROE of Ortin Laboratories Ltd is 118 %.
What is the Face Value of Ortin Laboratories Ltd?
The Face Value of Ortin Laboratories Ltd is 10.0.